Objective To assess the predictability of outcome and evaluate the factors that may lead to treatment failure in patients with Graves’ disease who are treated with a single dose of radioiodine. Materials and methods This is a retrospective study of 123 patients (M: 42; F: 81) with Graves’ disease who received radioiodine therapy with a single fixed (10 mCi) dose for hyperthyroidism. Pretreatment age, sex, BMI, type of anti-thyroid drug used, propylthiouracil doses, iodine uptake, uptake ratio (4/24 h radioiodine uptake), and thyroid volume of the patients in whom radioiodine therapy succeeded or failed were compared. Results Post-therapy follow-up revealed that therapy failed in 22% of the patients. Iodine uptakes and uptake ratios and volumes were found to be significantly higher in patients in whom therapy failed. It was observed that uptake ratio was at least 1 in 25 patients (20%), and therapy failed in 20 (80%) of these patients. Of the 98 patients (80%) in whom uptake ratio was less than 1, therapy was unsuccessful in only seven (7%). Conclusion Uptake ratio is a simple index that may be used to predict the patients in whom therapy may fail or succeed. In patients with Graves’ disease who have an uptake ratio of less than 1, radioiodine appears to be an effective dose with high success rates. In contrast, because of the high rates of failure in patients with an uptake ratio of at least 1, use of radioiodine therapy at a dose of 10 mCi does not seem to be appropriate.
1 January 2022 in TURKISH JOURNAL OF MEDICAL SCIENCES
Background/aim: It isimportant to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. We here aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNAbased COVID-19 vaccine (BNT162b2-Pfizer/BioNTech) and to analyze possible factors affecting these changes. Materials and methods: Among the patients who underwent FDG PET/CT for any indication in our department between July 2021 and December 2021, 129 volunteer patients with a history of COVID-19 vaccination were included in this prospective observational study. Bilateral axillary lymph nodes, ipsilateral deltoid muscle, bone marrow, spleen, thyroid, and liver FDG uptakes were evaluated visually and semiquantitatively for each examination. Results: The frequencies of positive axillary lymph nodes after vaccination were 40%, 44.4%, 32.6%, and 44.7% in all, 1st dose, 2nd dose, and heterologous vaccination regimens groups, respectively. Maximum standardized uptake values of spleen, liver, and bone marrow were statistically high in patients with positive axillary lymph nodes than with negative ones (p < 0.05). Positive deltoid muscle uptake and diffusely increased thyroid uptake findings were observed in 10 and 8 patients, respectively. The median time interval between vaccination and imaging was 9.5 days for patients with positive axillary lymph nodes and 17 days for patients with negative nodes. In our study group, only 8 patients had a positive documented history of COVID-19 infection. Conclusion: Regional and systemic metabolic changes were occasionally found on FDG PET/CT imaging in patients who received the mRNA-based COVID-19 vaccine. To avoid these timely decreasing changes, we recommend managing the ideal timing of imaging or vaccination and taking a careful history
20 July 2013 in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
The metastases of breast cancer to bone marrow can mimic plasma cell neoplasia morphologically due to presence of plasma cell-like neoplastic cells and even positive staining for a carcinoma metastasis with plasma cell marker CD138/ Syndecan-1 may cause confusion in diagnosis. This case report details a 71-year-old female initially suspected of plasma cell myeloma due to hypercalcemia and multiple lytic bone lesions. However, a bone marrow biopsy revealed syndecan-1 positive metastatic lobular breast cancer mimicking a plasma cell neoplasm. Bone marrow aspirate smears and the bone marrow biopsy showed plasmacytoid cells that were strongly positive for syndecan-1, indicating metastatic lobular breast carcinoma. The overexpression of syndecan-1 was a critical marker in identifying the breast cancer cells, emphasizing the diagnostic challenges when syndecan-1 positive metastatic lobular BC presents with plasmacytoid features.
20 December 2025 in Online Türk Sağlık Bilimleri Dergisi
Objective: This study aims to evaluate the clinical value of F-18 fluorodeoxyglucose (FDG) dual-time-point (DTP) PET/CT with semiquantitative analyses for predicting therapy response in patients with malignant lymphoma (ML). Materials and Methods: We evaluated 847 lesions in 39 patients diagnosed with ML, including Hodgkin Lymphoma (HL) and aggressive and indolent non-Hodgkin lymphoma (NHL). We calculated metabolic tumor volume (MTV), standardized uptake value (SUVmax), and total glycolytic activity (TGA) for each lesion during early (60 min) and delayed (120 min) scans, along with retention indices (RI). Interim PET/CT was then performed, and the performance of SUVmax and TGA cutoff values for assessing treatment response (Complete Response (CR) and Partial Response (PR)) was analyzed using ROC curve analysis and multivariate logistic regression. Results: In a study of 847 lesions, 817 CR lesions from 31 patients and 30 PR lesions from 8 patients were examined. The results showed that ΔSUVmax, ΔTGA, and the retention index in TGA (RI-TGA) were significantly higher in PR lesions compared to CR lesions, whereas no difference was observed for RI-SUVmax. The cut-off values established were ΔSUVmax > 3.7, ΔTGA > 14.94, and RI-TGA > 26.85%, indicating a 3.5 times greater likelihood of PR. For patient-based assessments, change in whole-body TGA (ΔWB-TGA) with a cut-off of 181.98 was significant (sensitivity 100%, specificity 67.74%, PPV 44.4%, NPV 100%) Conclusions: ΔSUVmax, ΔTGA, and RI-TGA values may predict therapy response based on lesion evaluation, while only ΔWBTGA is a significant factor based on patient evaluation. Dual-time imaging and TGA assessment may help predict therapy responses and guide personalized treatment plans.